The digital health company has tapped Mike Alvarez to lead the company at a key inflection point in its history.

As we venture further into 2023, Glooko CEO Russ Johannesson shares his perspective on the connected care trends in digital therapeutics, remote patient monitoring, precision engagement and decentralized clinical trials expected this year.

Through a new partnership, the Hedia app, which provides bolus insulin dosing recommendations, will integrate with Glooko’s connected care platform, which lets patients share diabetes data with their healthcare providers.

In addition to gathering data from glucose monitors, insulin pumps, fitness trackers and other devices, Glooko’s diabetes management platform will offer guidance for a user’s upcoming bolus doses of insulin, thanks to a partnership with Hedia, a Danish algorithm-based insulin dosing company.

2023 is expected to be a year of advancements in connected care supporting patients with chronic conditions and their care teams. Glooko CEO Russ Johannesson shares his outlook on trends in digital therapeutics, precision engagement, remote patient monitoring and clinical trial management.

Smart insulin pens are a recent advancement making an impact on people living with diabetes. These connected pens can be used by anyone with the chronic condition that injects insulin and can sync with certain digital health apps, like Glooko, that store insulin, blood glucose, fitness and food data in one place.

Sanofi formed a partnership with Glooko to support its vision of insulin-based therapies connected with glucose monitoring devices that simplify blood glucose management for people with diabetes.